Peritoneal Carcinomatosis: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Peritoneal carcinomatosis (peritoneal metastasis, PM) describes the diffuse dissemination of malignant cells throughout the peritoneal cavity and its lining surfaces. It most commonly originates from colorectal cancer (approximately 20% of patients develop PM during their disease course), ovarian cancer (over 70% present with PM at diagnosis), gastric cancer (approximately 40%), appendiceal mucinous neoplasms (pseudomyxoma peritonei, PMP), and peritoneal mesothelioma. For most primary tumors, peritoneal metastasis represents Stage IV disease and historically carried very poor prognosis. However, the evolution of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has transformed outcomes for selected patients with limited peritoneal spread from colorectal, ovarian, appendiceal, and mesothelioma, offering the possibility of long-term survival or even cure in carefully chosen candidates. Peritoneal Carcinomatosis: Causes, Symptoms, Diagnosis and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Peritoneal Carcinomatosis: Causes, Symptoms, Diagnosis and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

Peritoneal metastasis occurs primarily via transcoelomic spread — malignant cells exfoliate from the primary tumor or from lymph node metastases and implant on peritoneal surfaces, where they establish metastatic deposits. Risk factors for PM development depend heavily on primary tumor characteristics: perforated or T4 colorectal cancer with peritoneal breach, mucinous colorectal histology (higher PM risk than non-mucinous), signet ring cell gastric cancer (virtually invariably peritoneal), advanced ovarian cancer at diagnosis, and rupture of appendiceal mucinous neoplasms producing pseudomyxoma peritonei. Secondary hematogenous seeding from blood-borne metastases to the peritoneum also contributes. Surgical disruption of tumor integrity during resection can seed PM. Lynch syndrome carriers with colorectal cancer have higher PM rates. Malignant ascites accelerates peritoneal tumor implantation.

Abdominal distension from malignant ascites is the most characteristic and distressing symptom, occurring in over 60% of patients with advanced PM. Progressive nausea, vomiting, and early satiety result from gastric outlet obstruction or tumor compression. Small bowel obstruction (malignant ileus) causes cramping abdominal pain, distension, and inability to tolerate oral intake. Diffuse abdominal pain and tenderness reflect peritoneal irritation and mesenteric involvement. Palpable omental 'cake' — a firm transverse mass above the umbilicus — is detected on examination in some patients. Insidious progressive weight loss, anorexia, cachexia, and performance status decline are universal as disease advances. Symptoms often represent deterioration of a known malignancy rather than a new presentation.

Contrast-enhanced CT of the abdomen and pelvis detects peritoneal deposits greater than 1 cm and characterizes ascites, but misses sub-centimeter implants and underestimates true PM extent in approximately 30-40% of patients. Diffusion-weighted MRI offers higher sensitivity for small implants on bowel serosa and mesentery. Diagnostic laparoscopy with systematic peritoneal exploration and peritoneal cancer index (PCI) scoring — dividing the abdomen into 13 regions each scored 0-3 for lesion size (total 0-39) — is the essential pre-operative tool for surgical planning and candidacy for CRS/HIPEC. Ascites cytology. Core biopsy of peritoneal deposits for histopathology and comprehensive molecular profiling including MSI/MMR, KRAS, BRAF, and HER2 to guide systemic therapy selection.

Systemic chemotherapy is the backbone of palliative treatment: FOLFOX or FOLFIRI plus bevacizumab or anti-EGFR antibodies (for RAS wild-type left-sided colorectal PM); carboplatin plus paclitaxel plus bevacizumab for ovarian PM; FLOT for gastric PM. For selected patients with limited peritoneal disease and low PCI score: cytoreductive surgery (CRS) to achieve complete cytoreduction (CCR-0 or CCR-1) followed by HIPEC using oxaliplatin (colorectal), cisplatin plus mitomycin-C (ovarian), or mitomycin-C alone (appendiceal) at specialized centers offering potential curative intent. PIPAC (pressurized intraperitoneal aerosol chemotherapy) delivers palliative peritoneal drug concentrations via laparoscopy in patients ineligible for CRS/HIPEC. Bevacizumab reduces ascites accumulation rate. Palliative paracentesis relieves symptomatic ascites. Nutritional support and palliative care are integral to management.

Prognosis for peritoneal carcinomatosis varies widely by primary tumor type, peritoneal cancer index (PCI) score, and completeness of cytoreduction. Ovarian cancer with complete cytoreduction (CCR-0) followed by platinum-taxane chemotherapy achieves median OS of 30-45 months and 5-year OS of approximately 25-35%; residual gross disease reduces median OS to 20-30 months. Colorectal peritoneal metastasis with low PCI (up to 12) and complete CRS/HIPEC achieves median OS of 40-50 months and 5-year OS of approximately 30-45% — representing a potentially curative approach for selected patients. Appendiceal pseudomyxoma peritonei treated with complete CRS/HIPEC achieves 5-year OS of approximately 70-85% and 10-year OS of 60-70% for low-grade appendiceal mucinous neoplasm. Gastric peritoneal metastasis treated with systemic chemotherapy alone: median OS 4-9 months; highly selected patients in specialized centers achieve median OS of 18 months with CRS/HIPEC. Peritoneal mesothelioma with CRS/HIPEC achieves median OS of 40-60 months and 5-year OS of approximately 45-55% at specialized centers. Completeness of cytoreduction (CCR-0 or -1) is the single most powerful predictor of long-term survival across all tumor types. High PCI (greater than 20 for colorectal), poor performance status, aggressive histology, and systemic metastases contraindicate surgery and portend poor prognosis without curative intent. Monitoring includes CT or MRI every 3-6 months, tumor markers, and ascites assessment at each clinical visit.

Prevention of peritoneal carcinomatosis relies on optimal management of the primary cancer: complete (R0) resection of colorectal cancer without perforation, early-stage surgery before disease extends to peritoneal surfaces, and surveillance colonoscopy for post-resection follow-up in colorectal cancer. Colorectal cancer screening (colonoscopy from age 45) prevents the precancerous adenomas that progress to cancer and peritoneal spread. Laparoscopic rather than open surgery for colorectal cancer may reduce peritoneal seeding. For patients with ruptured appendiceal mucinous neoplasms (primary PMP source), referral to a specialized CRS/HIPEC center for prophylactic peritonectomy should be considered. Lynch syndrome carriers require annual colonoscopic surveillance to detect colorectal cancer at early, localized stages before peritoneal spread occurs.

Patients with a known primary cancer (colorectal, ovarian, gastric, appendiceal) should seek immediate evaluation for: new abdominal distension or rapidly accumulating ascites; progressive abdominal pain unexplained by the primary tumor; inability to tolerate oral intake or early satiety indicating gastric/bowel obstruction; or imaging demonstrating new peritoneal or omental disease. Known peritoneal carcinomatosis patients who wish to explore surgical options (CRS/HIPEC candidacy) should be referred to a specialized center with established CRS/HIPEC expertise for PCI staging laparoscopy and multidisciplinary team assessment. Early referral to palliative care is appropriate for all patients with symptomatic PM, regardless of whether active cancer treatment is ongoing, to optimize symptom management including ascites, pain, and nutritional support.